Scilex Holding Co (SCLX)
Scilex Holding Co is a healthcare company focused on non-opioid therapies for acute and chronic pain. The company markets ZTlido, a topical lidocaine prescription product for neuropathic pain associated with postherpetic neuralgia; ELYXYB, an oral solution for the acute treatment of migraine in adults; and GLOPERBA, a liquid oral colchicine product used to help prevent painful gout flares. Scilex is also advancing several development-stage programs, including SP-102 (SEMDEXA) for lumbosacral radicular pain or sciatica, SP-103 for chronic neck and low back pain, and SP-104 for fibromyalgia. In addition, the company has collaboration agreements with Oishi and Itochu for lidocaine tape products and with Lifecore Biomedical for clinical trial material manufacturing and development services related to SEMDEXA. Scilex is based in Palo Alto, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SCLX
|
$10.36
|
33.9% Upside
|
Undervalued
|
$490 6,230.8% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 13, 2026
|
-0.1x
|
-0.2x
|
1.6x
|
53.732 M
|
68.653 M
|
68.5%
|
80.9%
|
-12.6
|
—
|
0.8%
|
